TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Free Report) shares traded down 8.1% during trading on Wednesday . The company traded as low as $0.66 and last traded at $0.68. 1,056,975 shares changed hands during trading, a decline of 20% from the average session volume of 1,324,074 shares. The stock had previously closed at $0.74.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of TransCode Therapeutics in a research report on Friday, September 6th.
Check Out Our Latest Report on RNAZ
TransCode Therapeutics Stock Down 8.1 %
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.16). Sell-side analysts expect that TransCode Therapeutics, Inc. will post -2.06 earnings per share for the current year.
Hedge Funds Weigh In On TransCode Therapeutics
A hedge fund recently bought a new stake in TransCode Therapeutics stock. Virtu Financial LLC purchased a new stake in TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned approximately 0.84% of TransCode Therapeutics as of its most recent SEC filing.
About TransCode Therapeutics
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
See Also
- Five stocks we like better than TransCode Therapeutics
- Profitably Trade Stocks at 52-Week Highs
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Upcoming IPO Stock Lockup Period, Explained
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.